IGM Biosciences, Inc.
IGMS
$1.25
$0.054.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.68M | 2.68M | 2.92M | 2.91M | 2.11M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.68M | 2.68M | 2.92M | 2.91M | 2.11M |
| Cost of Revenue | 131.94M | 155.02M | 184.21M | 192.83M | 206.55M |
| Gross Profit | -129.25M | -152.35M | -181.30M | -189.92M | -204.44M |
| SG&A Expenses | 42.13M | 41.71M | 51.43M | 45.18M | 47.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 174.07M | 196.73M | 235.65M | 238.01M | 254.06M |
| Operating Income | -171.39M | -194.05M | -232.73M | -235.10M | -251.95M |
| Income Before Tax | -198.87M | -195.80M | -219.60M | -219.92M | -236.33M |
| Income Tax Expenses | -- | -- | 242.00K | 482.00K | 591.00K |
| Earnings from Continuing Operations | -198.87 | -195.80 | -219.84 | -220.40 | -236.92 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -198.87M | -195.80M | -219.84M | -220.40M | -236.92M |
| EBIT | -171.39M | -194.05M | -232.73M | -235.10M | -251.95M |
| EBITDA | -162.18M | -184.94M | -223.79M | -226.21M | -243.16M |
| EPS Basic | -3.27 | -3.24 | -3.65 | -3.68 | -4.31 |
| Normalized Basic EPS | -1.73 | -1.94 | -2.28 | -2.29 | -2.69 |
| EPS Diluted | -3.27 | -3.24 | -3.65 | -3.68 | -4.31 |
| Normalized Diluted EPS | -1.73 | -1.94 | -2.28 | -2.29 | -2.69 |
| Average Basic Shares Outstanding | 243.10M | 242.06M | 241.04M | 239.96M | 224.65M |
| Average Diluted Shares Outstanding | 243.10M | 242.06M | 241.04M | 239.96M | 224.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |